

50454-56101USCIP3**09/470,603**

APPLICANT

Eugenio Cefali

FILING DATE

31 October 1997

GROUP

1615U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)
(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO/ OR ABSTRACT

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

1	Expert Report of Cheryl D. Blume, Ph.D. (January 27, 2004) - Subject to Protective Order
2	Expert Report of Dr. Sergio Fazio (February 4, 2004) [Redacted Version] - Subject to Protective Order
3	Rebuttal Expert Report of Dr. Sergio Fazio (April 2, 2004) - Subject to Protective Order
4	Expert Report of Dr. Sergio Fazio Regarding U.S. Patent No. 6,676,967 (August 17, 2004) - Subject to Protective Order
5	Expert Report of Don W. Martens (February 6, 2004) [Redacted Version] - Subject to Protective Order
6	Expert Report of Don W. Martens Regarding U.S. Patent No. 6,676,967 (August 20, 2004) [Redacted Version] - Subject to Protective Order
7	Expert Report of Dr. Joseph R. Robinson (February 5, 2004) [Redacted Version] - Subject to Protective Order
8	Expert Report of Dr. Joseph R. Robinson Regarding U.S. Patent No. 6,676,967 (August 18, 2004) - Subject to Protective Order
9	Rebuttal Expert Report of Thomas S. Foster, Pharm.D. (April 2, 2004) - Subject to Protective Order

10	Rebuttal Expert Report of Thomas S. Foster, Pharm.D. Regarding The '967 Patent (October 4, 2004) - Subject to Protective Order
11	Rebuttal Expert Report of James W. McGinity, Ph.D. (April 2, 2004) - Subject to Protective Order
12	Supplemental Rebuttal Expert Report of James W. McGinity, Ph.D. (August 18, 2004) - Subject to Protective Order
13	Rebuttal Expert Report of James W. McGinity, Ph.D. Regarding The '967 Patent (September 30, 2004) - Subject to Protective Order
14	Expert Report of Mark E. McGovern, M.D. (February 6, 2004) - Subject to Protective Order
15	Expert Report of Mark E. McGovern, M.D. (August 20, 2004) - Subject to Protective Order
16	Expert Report of Frank M. Sacks, M.D. (April 2, 2004) - Subject to Protective Order
17	Expert Report of Frank M. Sacks, M.D. (August 20, 2004) - Subject to Protective Order
18	Rebuttal Expert Report of Mary Ann Tucker, Esq. (April 2, 2004) - Subject to Protective Order
19	Rebuttal Expert Report of Mary Ann Tucker, Esq. Regarding The '967 Patent (October 1, 2004) - Subject to Protective Order
20	Carl J. Lavie, et al., <i>Marked Benefit with Sustained-Release Niacin Therapy in Patients with Isolated@ Very Low Levels of High-Density Lipoprotein Cholesterol and Coronary Artery Disease</i>, Am. J. Cardiol. 1992:69:1083-1085
21	Excerpts from the 1993, 2000, and 2002 editions of the Physician's Desk Reference
22	<i>Niacin: Double-edged Sword for Lowering Cholesterol</i>, Tufts University Diet & Nutritional Letter (Tufts Univ., Boston, MA), August 1994, Vol. 12, issue 6
23	Larsen, ML and Illingworth, DR, <i>Drug Treatment of Dyslipoproteinemia</i>, Med Clin N Am., 78:225-245 (1994)
24	Lavie, Letter to Editor, JAMA 1994; 272:513-515

	25	Keenan, Letter to Editor, JAMA 1994; 272:513-515
	26	Shields & Beckmann, Letter to Editor, JAMA 1994; 272:513-515
	27	Thomas N. Tozer, Clinical Pharmacokinetics Concepts and Applications (3d ed. 1995) at Chapter 9, p. 120
	28	Excerpts from the United States Pharmacopeia (1995)
	29	Morgan & Capuzzi Abstract, <i>Safe and Effective Treatment of Dyslipidemia by Niaspan, a New Sustained-Release Niacin</i> , Clinical Pharmacology & Therapeutics (February 1996)
	30	Morgan & Capuzzi Article, <i>Treatment Effect of Niaspan, a Controlled-release Niacin, in Patients With Hypercholesterolemia: A Placebo-controlled Trial</i> , J. Cardiovasc. Pharmacol. Therapeut. 1(3):195-202 (July 1996)
	31	Capuzzi DM, et al., <i>Efficacy and Safety of An Extended-Release Niacin (Niaspan): A Long-Term Study</i> , Am J Cardiol. 1998;82:74U-81U
	32	Guyton JR, <i>Advances in Dyslipidemia: Discussion Session II</i> , Am J Cardiol, 1998; 82(12A): 85U-86U
	33	Knopp RH, et al., <i>Equivalent Efficacy of a Time-Release Form of Niacin (Niaspan) Given Once-a-Night Versus Plain Niacin in the Management of Hyperlipidemia</i> , Metabolism 47:1097-1104 (1998)
	34	American Diabetes Association: <i>Management of Dyslipidemia in Adults with Diabetes</i> , Diabetes Care 21:179-182, 1998
	35	Elam MB, et al., <i>Effect of Niacin on Lipid and Lipoprotein Levels and Glycemic Control in Patients With Diabetes and Peripheral Arterial Disease</i> , JAMA: 2000; 284:1263-1270
	36	Kesala R, et al., <i>Niacin (N) vs. Niaspan (NS) Treatment of the Atherogenic Lipid Profile (ALP; Small, Dense LDL, HDL2, HDLc and Triglycerides) and Lp(a) in Diabetic Patients (DP)</i> , Diabetes 49 (suppl. 1): A268 at 1114-P (June 2000)
	37	2001 NCEP Report at VI-11, Table VI.2-3
	38	Wang, W. et al., <i>Effect of Nicotinic Acid Administration on Hepatic Very Low Density Lipoprotein-Triglyceride Production</i> , Am J Physiol Endocrinol Metab., 280:E540-E547 (2001)

	39	Smith SC, et al., <i>AHA/ACC Guidelines for Preventing Heart Attack and Death in Patients with Atherosclerotic Cardiovascular Disease: 2001 Update</i>. AHA/ACC Scientific Statement, 1577-79
	40	Tavintharan S and Kashyap M, <i>The Benefits of Niacin in Atherosclerosis</i>, Curr Athero. Reports 2001; 3:74-82
	41	Meadows M., <i>Serious Liver Injury: Leading Reason for Drug Removals, Restrictions</i>, FDA Consumer Magazine, May-June 2001; http://www.fda.gov/fdac/features/2001/301_liver.html
	42	Grundy SM, et al., <i>Efficacy, Safety, and Tolerability of Once-Daily Niacin for the Treatment of Dyslipidemia Associated with Type 2 Diabetes</i>. Arch Intern Med. 2002; 162: 1568-1576
	43	American Diabetes Association: <i>Management of Dyslipidemia in Adults with Diabetes</i>, Diabetes Care 25:S74-S77, 2002
	44	Pan J, et al., <i>Niacin Treatment of the Atherogenic Lipid Profile and Lp(a) in Diabetes</i>, Diabetes, Obesity and Metabolism 4:255-261 (2002)
	45	Pan J, et al., <i>Extended-Release Niacin Treatment of the Atherogenic Lipid Profile and Lipoprotein(a) in Diabetes</i>, Metabolism 51:1120-1127 (2002)
	46	Meyers CD, et al., <i>Varying Cost and Free Nicotinic Acid Content in Over-the-Counter Niacin Preparations for Dyslipidemia</i>, Ann Intern Med. 2003; 139:996-1002
	47	CDER <i>Guidance for Industry, Bioavailability and Bioequivalence Studies for Orally Administered Drug Products - General Considerations</i> (March 2003)
	48	American Diabetes Association: <i>Dyslipidemia Management in Adults with Diabetes</i>, Diabetes Care 27:S68-S71, 2004
	49	Sample Kos Clinical Trial Medical Consent Form - Subject to Protective Order
	50	Sample Kos Clinical Trial Investigator's Statement - Subject to Protective Order
EXAMINER		DATE CONSIDERED